中医肿瘤学杂志2026，Vol.8Issue(4)：33-41,9.DOI:10.19811/j.cnki.ISSN2096-6628.2026.07.005
原发性肝癌中医专病队列长期随访结果
Long-Term Follow-Up Outcomes of a Traditional Chinese Medicine Disease-Specific Cohort for Primary Liver Cancer
摘要
Abstract
Objective To update long-term outcomes from a previously reported traditional Chinese medicine(TCM)disease-specific cohort for primary liver cancer,and to evaluate the efficacy of TCM syndrome-based treatment guided by Chinese medicine master Professor Zhou Daihan in patients with liver cancer.Methods This retrospective cohort study included 223 primary liver cancer patients treated by Professor Zhou from September 2020 and December 2022.Patients were divided into a curative subcohort(119 cases)and a non-curative subcohort(101 cases),and were further divided into exposed and non-exposed group according to their receipt of standardized(timely and regular)TCM syndrome-based treatment.The primary endpoints were time to recurrence(TTR)and overall survival(OS).Propensity score matching(PSM)was used to minimize confounding.Survival curves were estimated using the Kaplan-Meier method,between-group differences were assessed with the log-rank test,and hazard ratios(HRs)were calculated via Cox regression.The follow-up was updated as of October 18,2025,providing new 5-year,7-year,and 10-year survival data.Results In the curative subcohort(52 patients per group after PSM),the exposed group had a significantly longer median TTR than the non-exposed group(51.2 months vs 10.5 months,HR=0.30,95%CI:0.19～0.48,P＜0.001).The 7-year and 10-year recurrence-free survival rates were 37.5%vs 5.7%and 37.5%vs 3.9%,respectively.The median OS was not reached in the exposed group versus 65.0 months in the non-exposed group(HR=0.41,95%CI:0.22～0.79,P＜0.010),with 10-year OS rates of 66.1%and 39.6%,respectively.In the non-curative subcohort,median OS was significantly longer in the exposed group than in the non-exposed group(22.4 months vs 9.7 months,HR=0.57,95%CI:0.36～0.89,P=0.020),and the 5-year OS rate was 17.6%in the exposed group versus 0 in the non-exposed group.Multivariate Cox regression identified TCM syndrome-based treatment as an independent protective factor for both TTR and OS.Conclusion TCM syndrome-based treatment,grounded in Professor Zhou Daihan's"survival with tumor"philosophy,can significantly delay postoperative recurrence,prolong survival in patients with unresectable disease,and achieve long-term survival benefits.关键词
原发性肝癌/中医辨证施治/队列研究/长期随访Key words
primary liver cancer/traditional Chinese medicine syndrome-based treatment/cohort study/long-term follow-up分类
医药卫生引用本文复制引用
陈虹宇,周瑞生,唐莹,吴岱琳,甄宏德,庄振杰,高天琦,潘艳丽,周岱翰..原发性肝癌中医专病队列长期随访结果[J].中医肿瘤学杂志,2026,8(4):33-41,9.基金项目
国家自然科学基金(编号:82575167) （编号:82575167）
深圳市"医疗卫生三名工程"项目(编号:SZZYSM202311011) （编号:SZZYSM202311011）
广州市卫健委国医大师传承创新工程项目(编号:穗卫中医[2025]2号) （编号:穗卫中医[2025]2号）
广州地区中西医协同临床重大创新技术建设项目 （）
广州中医药大学第一附属医院2025年周岱翰国医大师学术思想传承项目(编号:08003007015). （编号:08003007015）
